Review





Similar Products

96
Miltenyi Biotec cells
Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd11b+cells/CD11b+MicroBeads%2C+human+and+mouse/pm42468469-103-3-9
Average 96 stars, based on 1 article reviews
cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Miltenyi Biotec single cell suspensions
Single Cell Suspensions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd11b+cells/CD11b+MicroBeads+UltraPure%2C+mouse/bio_rxiv__64898__2026__06__04__730038-363-13-32
Average 95 stars, based on 1 article reviews
single cell suspensions - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Miltenyi Biotec cell suspension
Cell Suspension, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd11b+cells/CD11b+(Microglia)+MicroBeads%2C+human+and+mouse+-+small+size/pmc13218475-177-9-25
Average 96 stars, based on 1 article reviews
cell suspension - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd11b magnetic activated cell sorting macs system
Cd11b Magnetic Activated Cell Sorting Macs System, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd11b+cells/CD11b+MicroBeads%2C+human+and+mouse+-+lyophilized/pm42142538-61-20-26
Average 96 stars, based on 1 article reviews
cd11b magnetic activated cell sorting macs system - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

98
Miltenyi Biotec cd11b cells
Targeting USP14 inhibits tumor growth and induces local anti-tumor immunity in vivo (A) Representative images of MC38 tumors harvested on day 21 post-inoculation from mice treated with IU1 (20 mg/kg, i.p., on days 6, 9, 12, and 15) or vehicle control. (B) Statistics of MC38 tumor growth rate following IU1 or vehicle treatment in vivo . The intraperitoneal injection dose of IU1 was 20 mg/kg, administered on days 6, 9, 12, and 15. Data are presented as the mean ± SEM ( n = 6 per group). (C) Spider diagram of the tumor volume growth in each mouse from the IU1 group and the PBS group. (D) Gating strategy for the detection of the TAMs by flow cytometry. We first obtained live cells, and then identified cells that were positive for CD45, <t>CD11b,</t> F4-80, and CD206 as M2 macrophages. (E–P) Proportions of neutrophil (E), M2 macrophage (F), M1 macrophage (G), MDSC (H), activated DCs (I), CD4 T cell (J), Treg cells (K), CD8 T cell (L), IFN-γ + CD8 T cell (M), precursor exhausted T cells (TCF-1 + ) (N), effective CD8 T cells (PD-1 + ) (O) and activated CD8 T cell (CD69 + ) (P) in the TME of the IU1 group and the control group by using flow cytometry. (Q–U) Cytokines IFN-γ (Q), TNF-α (R), IL-2 (S), IL-10 (T), and IL-12 (U) in the TME of each group were detected by Mul-Analyte Flow Assay Kit. (V) Schematic illustration of the proposed mechanism of action of IU1 in reprogramming the tumor microenvironment. Data are presented as the mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001, and ns: not significant.
Cd11b Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd11b+cells/CD11b%2Fc+Antibody%2C+anti-rat%2C+REAfinity/pmc13122227-330-5-19
Average 98 stars, based on 1 article reviews
cd11b cells - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

95
Miltenyi Biotec mouse bone marrow cells
Targeting USP14 inhibits tumor growth and induces local anti-tumor immunity in vivo (A) Representative images of MC38 tumors harvested on day 21 post-inoculation from mice treated with IU1 (20 mg/kg, i.p., on days 6, 9, 12, and 15) or vehicle control. (B) Statistics of MC38 tumor growth rate following IU1 or vehicle treatment in vivo . The intraperitoneal injection dose of IU1 was 20 mg/kg, administered on days 6, 9, 12, and 15. Data are presented as the mean ± SEM ( n = 6 per group). (C) Spider diagram of the tumor volume growth in each mouse from the IU1 group and the PBS group. (D) Gating strategy for the detection of the TAMs by flow cytometry. We first obtained live cells, and then identified cells that were positive for CD45, <t>CD11b,</t> F4-80, and CD206 as M2 macrophages. (E–P) Proportions of neutrophil (E), M2 macrophage (F), M1 macrophage (G), MDSC (H), activated DCs (I), CD4 T cell (J), Treg cells (K), CD8 T cell (L), IFN-γ + CD8 T cell (M), precursor exhausted T cells (TCF-1 + ) (N), effective CD8 T cells (PD-1 + ) (O) and activated CD8 T cell (CD69 + ) (P) in the TME of the IU1 group and the control group by using flow cytometry. (Q–U) Cytokines IFN-γ (Q), TNF-α (R), IL-2 (S), IL-10 (T), and IL-12 (U) in the TME of each group were detected by Mul-Analyte Flow Assay Kit. (V) Schematic illustration of the proposed mechanism of action of IU1 in reprogramming the tumor microenvironment. Data are presented as the mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001, and ns: not significant.
Mouse Bone Marrow Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd11b+cells/CD11b+MicroBeads+UltraPure%2C+mouse/pmc12995707-369-9-20
Average 95 stars, based on 1 article reviews
mouse bone marrow cells - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


Targeting USP14 inhibits tumor growth and induces local anti-tumor immunity in vivo (A) Representative images of MC38 tumors harvested on day 21 post-inoculation from mice treated with IU1 (20 mg/kg, i.p., on days 6, 9, 12, and 15) or vehicle control. (B) Statistics of MC38 tumor growth rate following IU1 or vehicle treatment in vivo . The intraperitoneal injection dose of IU1 was 20 mg/kg, administered on days 6, 9, 12, and 15. Data are presented as the mean ± SEM ( n = 6 per group). (C) Spider diagram of the tumor volume growth in each mouse from the IU1 group and the PBS group. (D) Gating strategy for the detection of the TAMs by flow cytometry. We first obtained live cells, and then identified cells that were positive for CD45, CD11b, F4-80, and CD206 as M2 macrophages. (E–P) Proportions of neutrophil (E), M2 macrophage (F), M1 macrophage (G), MDSC (H), activated DCs (I), CD4 T cell (J), Treg cells (K), CD8 T cell (L), IFN-γ + CD8 T cell (M), precursor exhausted T cells (TCF-1 + ) (N), effective CD8 T cells (PD-1 + ) (O) and activated CD8 T cell (CD69 + ) (P) in the TME of the IU1 group and the control group by using flow cytometry. (Q–U) Cytokines IFN-γ (Q), TNF-α (R), IL-2 (S), IL-10 (T), and IL-12 (U) in the TME of each group were detected by Mul-Analyte Flow Assay Kit. (V) Schematic illustration of the proposed mechanism of action of IU1 in reprogramming the tumor microenvironment. Data are presented as the mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001, and ns: not significant.

Journal: iScience

Article Title: Targeting USP14 enhances immunotherapy response by reprogramming tumor-associated macrophages in colon cancer

doi: 10.1016/j.isci.2026.115362

Figure Lengend Snippet: Targeting USP14 inhibits tumor growth and induces local anti-tumor immunity in vivo (A) Representative images of MC38 tumors harvested on day 21 post-inoculation from mice treated with IU1 (20 mg/kg, i.p., on days 6, 9, 12, and 15) or vehicle control. (B) Statistics of MC38 tumor growth rate following IU1 or vehicle treatment in vivo . The intraperitoneal injection dose of IU1 was 20 mg/kg, administered on days 6, 9, 12, and 15. Data are presented as the mean ± SEM ( n = 6 per group). (C) Spider diagram of the tumor volume growth in each mouse from the IU1 group and the PBS group. (D) Gating strategy for the detection of the TAMs by flow cytometry. We first obtained live cells, and then identified cells that were positive for CD45, CD11b, F4-80, and CD206 as M2 macrophages. (E–P) Proportions of neutrophil (E), M2 macrophage (F), M1 macrophage (G), MDSC (H), activated DCs (I), CD4 T cell (J), Treg cells (K), CD8 T cell (L), IFN-γ + CD8 T cell (M), precursor exhausted T cells (TCF-1 + ) (N), effective CD8 T cells (PD-1 + ) (O) and activated CD8 T cell (CD69 + ) (P) in the TME of the IU1 group and the control group by using flow cytometry. (Q–U) Cytokines IFN-γ (Q), TNF-α (R), IL-2 (S), IL-10 (T), and IL-12 (U) in the TME of each group were detected by Mul-Analyte Flow Assay Kit. (V) Schematic illustration of the proposed mechanism of action of IU1 in reprogramming the tumor microenvironment. Data are presented as the mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001, and ns: not significant.

Article Snippet: For RNA and protein extraction, CD11b + cells were first enriched using magnetic-activated cell sorting (MACS) with anti-CD11b microbeads (Miltenyi Biotec) according to the manufacturer’s protocol.

Techniques: In Vivo, Control, Injection, Flow Cytometry